New therapeutic concepts in bile acid transport and signaling for management of cholestasis
暂无分享,去创建一个
[1] J. Reguła,et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.
[2] Hanns-Ulrich Marschall,et al. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. , 2016, Cell metabolism.
[3] M. Trauner,et al. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease , 2016, Digestive Diseases.
[4] T. Baumert,et al. Hepatitis B virus receptors and molecular drug targets , 2016, Hepatology International.
[5] A. Baghdasaryan,et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. , 2016, Journal of hepatology.
[6] J. Lupski,et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis , 2016, Nature Communications.
[7] M. Kowgier,et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes , 2016, Alimentary pharmacology & therapeutics.
[8] R. M. Learned,et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice , 2015, Hepatology.
[9] A. Moschetta,et al. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 , 2015, Nature Reviews Drug Discovery.
[10] D. Häussinger,et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro , 2015, Gut.
[11] O. Barbier,et al. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease , 2015, Scientific Reports.
[12] J. Boyer,et al. Fibrates and cholestasis , 2015, Hepatology.
[13] D. Cassio,et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrate , 2015, Hepatology.
[14] F. Bäckhed,et al. Farnesoid X Receptor Inhibits Glucagon-Like Peptide-1 Production by Enteroendocrine L-cells , 2015, Nature Communications.
[15] U. Beuers,et al. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na+-taurocholate cotransporting polypeptide knockout mice , 2015, Hepatology.
[16] M. Trauner,et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.
[17] K. Lindor,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.
[18] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[19] D. Adams,et al. Novel therapeutic targets in primary biliary cirrhosis , 2015, Nature Reviews Gastroenterology &Hepatology.
[20] H. Verkade,et al. Bile Acid Pool Dynamics in Progressive Familial Intrahepatic Cholestasis With Partial External Bile Diversion , 2015, Journal of pediatric gastroenterology and nutrition.
[21] V. Balasubramaniyan,et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. , 2015, Journal of hepatology.
[22] D. Brenner,et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance , 2015, Nature Medicine.
[23] I. Albert,et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.
[24] H. Waterham,et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype , 2015, Hepatology.
[25] D. Lindhout,et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases , 2014, Science Translational Medicine.
[26] H. Mellor,et al. Targeted inhibition of the FGF19‐FGFR4 pathway in hepatocellular carcinoma; translational safety considerations , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[27] T. Arora,et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. , 2014, Cancer research.
[28] T. Tordjmann,et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice , 2013, Hepatology.
[29] A. Lohse,et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. , 2013, Journal of hepatology.
[30] F. Cattaruzza,et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. , 2013, The Journal of clinical investigation.
[31] S. Kliewer,et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. , 2013, American journal of physiology. Gastrointestinal and liver physiology.
[32] F. Bäckhed,et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.
[33] M. Trauner,et al. Bile acid transporters and regulatory nuclear receptors in the liver and beyond , 2013, Journal of hepatology.
[34] J. Boyer,et al. Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.
[35] H. Sokol,et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases , 2012, Gut.
[36] J. Reguła,et al. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease , 2012, BMC Research Notes.
[37] M. Trauner,et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. , 2012, Gastroenterology.
[38] S. Spiegel,et al. Conjugated bile acids activate the sphingosine‐1‐phosphate receptor 2 in primary rodent hepatocytes , 2012, Hepatology.
[39] C. Paulusma,et al. A biliary HCO3− umbrella constitutes a protective mechanism against bile acid‐induced injury in human cholangiocytes , 2012, Hepatology.
[40] A. Baghdasaryan,et al. Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO 3− output , 2011, Hepatology.
[41] A. S. Andreasen,et al. Type 2 Diabetes Is Associated with Altered NF-κB DNA Binding Activity, JNK Phosphorylation, and AMPK Phosphorylation in Skeletal Muscle after LPS , 2011, Front. Nutr..
[42] S. Kliewer,et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. , 2011, Molecular endocrinology.
[43] S. Kliewer,et al. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.
[44] Lincoln D. Stein,et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.
[45] M. Trauner,et al. Nuclear receptors in liver disease , 2011, Hepatology.
[46] G. Hirschfield,et al. Pathogenesis of cholestatic liver disease and therapeutic approaches. , 2010, Gastroenterology.
[47] R. D. de Man,et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.
[48] C. Wijmenga,et al. Genome-wide association analysis in primary sclerosing cholangitis. , 2010, Gastroenterology.
[49] D. Häussinger,et al. The membrane‐bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders , 2009, Hepatology.
[50] D. Gouma,et al. High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis , 2009, Hepatology.
[51] B. M. Forman,et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.
[52] D. Häussinger,et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. , 2008, Biochemical and biophysical research communications.
[53] Richard J. Thompson,et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. , 2008, Gastroenterology.
[54] F. Lammert,et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. , 2007, Gastroenterology.
[55] S. Glaser,et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. , 2007, Gastroenterology.
[56] J. Auwerx,et al. Endocrine functions of bile acids , 2006, The EMBO journal.
[57] S. Kliewer,et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[58] K. Zatloukal,et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2006, Gastroenterology.
[59] S. Kliewer,et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.
[60] R. Blevins,et al. Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3* , 2003, Journal of Biological Chemistry.
[61] K. Zatloukal,et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. , 2003, Gastroenterology.
[62] Masataka Harada,et al. A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.
[63] H. Ackermann,et al. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study , 2002, European journal of gastroenterology & hepatology.
[64] Takao Nakamura,et al. Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.
[65] T. Willson,et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.
[66] G. Frantz,et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. , 2002, The American journal of pathology.
[67] P. Fisher,et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. , 2001, Molecular biology of the cell.
[68] M. Makishima,et al. Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.
[69] L. Moore,et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.
[70] A. Hofmann,et al. The continuing importance of bile acids in liver and intestinal disease. , 1999, Archives of internal medicine.
[71] A. Hofmann,et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. , 1999, Gastroenterology.
[72] M. Makishima,et al. Identification of a nuclear receptor for bile acids. , 1999, Science.
[73] J. Lehmann,et al. Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.
[74] Jasmine Chen,et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.
[75] J. Steinbach,et al. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. , 1986, Gastroenterology.
[76] B. Combes,et al. Beneficial effect of cholestyramine in sclerosing cholangitis. , 1980, Gastroenterology.
[77] P. Chiba,et al. Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury. , 2017, Journal of hepatology.
[78] M. Trauner,et al. Bile acids in regulation of inflammation and immunity: friend or foe? , 2016, Clinical and experimental rheumatology.
[79] A. Miethke,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Pharmacological Inhibition of Apical Sodium- Dependent Bile Acid Transporter Changes Bile Composition and Blocks Progression of Sclerosing Cholangitis in Multidrug Resistance 2 Knockout Mice , 2016 .
[80] S. Raimondo,et al. Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome. , 2016, Clinical and experimental rheumatology.
[81] H. Gohlke,et al. α5β1‐integrins are sensors for tauroursodeoxycholic acid in hepatocytes , 2013, Hepatology.
[82] H. Jaeschke,et al. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. , 2011, The American journal of pathology.
[83] B. Staels,et al. Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.
[84] R. Porte,et al. Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. , 2009, Journal of hepatology.
[85] K. Zatloukal,et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice , 2009, Hepatology.